(HealthDay News) – Surgical management of male breast cancer (MBC) is considerably different from that of female breast cancer (FBC), according to a study published in the Nov. 15 issue of the International Journal of Radiation Oncology • Biology • Physics.
Emma C. Fields, MD, from the University of Colorado School of Medicine in Aurora, and colleagues utilized data from the Surveillance, Epidemiology, and End Results database to identify all primary invasive breast cancer, male or female, diagnosed from 1973–2008.
The researchers found that there were 4,276 cases of MBC (0.6% of all cases) and 718,587 cases of FBC. Mastectomy was used in 87.4% of MBC cases vs. 38.3% of FBC, and breast-conserving surgery was used in 12.6% and 52.6%, respectively (P<10−4). For males with localized breast cancer, there was no significant difference in cause-specific survival (CSS) for the 4.6% treated with lumpectomy/radiation therapy (RT) vs. the 70% treated with mastectomy alone (hazard ratio, 1.33; P=0.57). For men with regional cancer, post-mastectomy RT was delivered in 33% of cases and was not associated with an improvement in CSS (hazard ratio, 1.11; P=0.37). Use of post-mastectomy RT in MBC increased significantly over time. CSS for MBC improved over time, with the largest significant change for men diagnosed in 1998–2008 vs. 1973–1987.
“Surgical management of MBC is dramatically different than for FBC,” the authors conclude.